Evidence map›Paper›PMID 41721140›Full record

ArticleJournal of neurology2026

Accuracy of clinical diagnosis in neurodegenerative diseases - a study of 455 autopsy cases.

Jonathan Vöglein, Thomas Arzberger, Irena Ebner, Jochen Herms, Sigrun Roeber, Viktoria Ruf, Adrian Danek, Armin Giese, Günter U Höglinger, Johannes Levin

Abstract read
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jonathan VögleinDepartment of Neurology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. jonathan.voeglein@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-5965-838X
Thomas ArzbergerGerman Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Straße 17, 81377, Munich, Germany.
Irena EbnerDepartment of Neurology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany.
Jochen HermsGerman Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Straße 17, 81377, Munich, Germany.
Sigrun RoeberCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Feodor-Lynen-Straße 17, 81377, Munich, Germany.
Viktoria RufCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Feodor-Lynen-Straße 17, 81377, Munich, Germany.
Adrian DanekDepartment of Neurology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany.
Armin GieseMODAG GmbH, Mikro-Forum-Ring 3, 55234, Wendelsheim, Germany.
Günter U HöglingerDepartment of Neurology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany.
Johannes LevinDepartment of Neurology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. johannes.levin@med.uni-muenchen.de.

Funding

Deutsche Forschungsgemeinschaft EXC 2145 SyNergy - ID 390857198
6 · The paper itself

Abstract

backgroundPrecision of clinical diagnosis in neurodegenerative diseases is critically important for clinical care and study recruitment. This study aimed to investigate the clinical accuracy using gold-standard neuropathological reference.

methodsNeuropathological diagnoses from the Neurobiobank München were correlated with real-world clinical diagnoses from hospitals in Germany. Accuracy metrics, including sensitivity, specificity, and area under the curve (AUC) of clinical diagnoses, were calculated.

resultsAmong nine neuropathologically diagnosed neurodegenerative diseases (Alzheimer's disease, argyrophilic grain disease, corticobasal degeneration, frontotemporal lobar degeneration, Huntington's disease, Lewy body disease, motor neuron disease, multiple system atrophy, and progressive supranuclear palsy) with a total of 455 cases, clinical sensitivity varied widely (0-100%) whereas specificity was consistently high (89.5-100%). Accuracy was very good (AUC > 0.9) for Huntington's disease, motor neuron disease, and multiple system atrophy; good (AUC = 0.8-0.9) for Alzheimer's disease, dementia with Lewy bodies/Parkinson's disease, and progressive supranuclear palsy; moderate (AUC = 0.7-0.8) for frontotemporal dementia, limited (AUC = 0.51-0.7) in the n = 20 cases with corticobasal degeneration, and no discriminatory capacity (AUC = 0.5) in the n = 6 cases with argyrophilic grain disease.

conclusionsClinical diagnostic accuracy of neurodegenerative diseases varies, with sensitivity as the main limiting factor. Improving diagnostic sensitivity will be essential for early and accurate patient identification, especially as disease-modifying therapies targeting causal proteinopathies become available. Achieving this will depend on the development and clinical implementation of reliable molecular biomarkers that indicate the causal proteinopathies of neurodegenerative diseases.

Indexed as

BrainNeurodegenerative DiseasesAgedAged, 80 and overAutopsyFemaleHumansMaleMiddle AgedSensitivity and SpecificityClinical diagnosisClinical–neuropathological correlationDiagnostic accuracyNeurodegenerative diseasesNeuropathology

Identifiers

PMID41721140
PMCPMC12923403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.